Clinical Trial · NCT03042416

18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety

Overview

Single centre prospective cohort phase III study of 18F-DOPA PET/CT imaging in specific patient populations: 1. Pediatric patients with congenital hyperinsulinism 2. Pediatric patients with neuroblastoma 3. Pediatric or Adult patients with suspected extra-pancreatic neuroendocrine tumor 4. Adult patients with a clinical suspicion of Parkinson's disease 5. Pediatric or Adult patients with primary brain tumors This study will evaluate the biodistribution and safety of 18F-DOPA produced at the Edmonton PET Centre.

Sponsor

University of Alberta

Phase

Phase 3

Contacts

Jonathan T Abele, MD (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT03042416

Eligibility

Inclusion

4\. Adult patients (17 or older) with a clinical suspicion of Parkinson's disease.

Exclusion

Lack of intravenous access
Adult patients unable to lie flat for 20-30 minutes to complete the PET/CT scan
Unable to obtain consent
Weight \> 250 kg (weight limitation of PET/CT scanner)
Pregnancy